Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Verve Therapeutics

Request full access

Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary

Cambridge, United StatesFounded 2018Biotech & Life Sciences

About Verve Therapeutics

Verve Therapeutics is a pioneering genetic medicines company focused on transforming the treatment of cardiovascular disease through innovative gene editing technologies. The company operates in the biotechnology sector, specifically targeting cardiovascular health. Verve's business model revolves around discovering and developing single-course gene editing medicines that aim to provide long-term solutions for patients, as opposed to traditional chronic management therapies. The initial programs target the PCSK9 and ANGPTL3 genes, which are well-validated for their roles in lowering blood lipid levels. Verve Therapeutics primarily serves patients suffering from cardiovascular diseases, offering them potentially curative treatments. The company generates revenue through the development and commercialization of its gene editing therapies, as well as potential partnerships and collaborations with other biotech firms and healthcare providers.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2021

Verve Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Verve Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A14 investors entered at this stage

Series B and later1 investor entered at this stage

  • Eli Lilly
Employees mapped 159 incl. 2 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 7 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$21M

11 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Verve Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.